By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

SALVAT 

C\ Gall, 30-36
Esplugues de Llobregat
Barcelona    08950  Spain
Phone: 349-3394-6400 Fax: 349-3473-2292


SEARCH JOBS


Industry
Pharmaceutical






Company News
SALVAT Completes Enrollment of Phase III Study for a New Combination in Acute Otitis Media in Pediatric Patients With Tympanostomy Tubes (AOMT) 5/28/2013 9:40:15 AM
SALVAT and Kwang Dong Pharmaceutical Announced Positive Results of Phase IIb for Tarafenacin for Overactive Bladder Treatment 4/10/2013 6:42:51 AM
Laboratorios SALVAT, S.A. and WraSer Pharmaceuticals, LLC Announce Exclusive License Agreement for the Commercialization of CETRAXAL(R) (ciprofloxacin otic solution) 0.2% 7/8/2009 11:14:27 AM
SALVAT Announces Submission of Complete Response to FDA Approvable Letter for CETRAXAL(R) 11/6/2008 10:01:10 AM
SALVAT Has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT-40776 for the Treatment of Overactive Bladder 10/10/2007 11:08:29 AM
SALVAT has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT-40776 10/10/2007 7:34:36 AM
Chiesi Farmaceutici SpA And SALVAT Sign A Worldwide Development And Licensing Agreement For M3 Muscarinic Receptor Antagonists 1/9/2006 12:30:24 PM
SALVAT Seeks FDA Approval For Its CETRAXAL Otic (Ciprofloxacin Otic) 0.2% Solution, For The Treatment Of External Otitis10/19/2005 5:13:04 PM
SALVAT Seeks FDA Approval For its CETRAXAL Otic (ciprofloxacin otic) 0.2% Solution, For The Treatment Of External Otitis10/19/2005 5:10:58 PM
SALVAT Seeks FDA Approval For Its CETRAXAL Otic (ciprofloxacin otic) 0.2% Solution, For The Treatment Of External Otitis10/19/2005 5:10:20 PM
12
//-->